ERAS
Price
$11.24
Change
+$0.65 (+6.14%)
Updated
Feb 4 closing price
Capitalization
3.48B
42 days until earnings call
Intraday BUY SELL Signals
INBX
Price
$82.56
Change
-$2.52 (-2.96%)
Updated
Feb 4 closing price
Capitalization
1.2B
46 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs INBX

Header iconERAS vs INBX Comparison
Open Charts ERAS vs INBXBanner chart's image
Erasca
Price$11.24
Change+$0.65 (+6.14%)
Volume$4.11M
Capitalization3.48B
Inhibrx Biosciences
Price$82.56
Change-$2.52 (-2.96%)
Volume$170.57K
Capitalization1.2B
ERAS vs INBX Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
INBX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. INBX commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and INBX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ERAS: $11.24 vs. INBX: $82.56)
Brand notoriety: ERAS and INBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 69% vs. INBX: 76%
Market capitalization -- ERAS: $3.48B vs. INBX: $1.2B
ERAS [@Biotechnology] is valued at $3.48B. INBX’s [@Biotechnology] market capitalization is $1.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileINBX’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • INBX’s FA Score: 1 green, 4 red.
According to our system of comparison, INBX is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while INBX’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 5 bearish.
  • INBX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, INBX is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +10.96% price change this week, while INBX (@Biotechnology) price change was +11.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.81%. For the same industry, the average monthly price growth was +0.47%, and the average quarterly price growth was +32.90%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

INBX is expected to report earnings on Mar 23, 2026.

Industries' Descriptions

@Biotechnology (-3.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($3.48B) has a higher market cap than INBX($1.2B). ERAS YTD gains are higher at: 202.151 vs. INBX (4.506). ERAS has higher annual earnings (EBITDA): -131.32M vs. INBX (-143.46M). ERAS has more cash in the bank: 288M vs. INBX (153M). ERAS has less debt than INBX: ERAS (48.3M) vs INBX (107M). INBX has higher revenues than ERAS: INBX (1.4M) vs ERAS (0).
ERASINBXERAS / INBX
Capitalization3.48B1.2B290%
EBITDA-131.32M-143.46M92%
Gain YTD202.1514.5064,486%
P/E RatioN/A0.20-
Revenue01.4M-
Total Cash288M153M188%
Total Debt48.3M107M45%
TECHNICAL ANALYSIS
Technical Analysis
ERASINBX
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 11 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
INBX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NWAYX14.600.20
+1.39%
Nationwide GQG US Quality Eq Eagle
FSCZX30.40N/A
N/A
Fidelity Advisor Stk Selec Lg Cp Val Z
TEPLX28.97-0.02
-0.07%
Templeton Growth A
CDWFX15.03-0.01
-0.07%
American Funds Dvlpg Wld Gr&Inc 529F1
PGKCX25.84-0.69
-2.60%
PGIM Jennison Technology C

INBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, INBX has been closely correlated with ACET. These tickers have moved in lockstep 86% of the time. This A.I.-generated data suggests there is a high statistical probability that if INBX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INBX
1D Price
Change %
INBX100%
-2.96%
ACET - INBX
86%
Closely correlated
-3.51%
TERN - INBX
82%
Closely correlated
-6.39%
ERAS - INBX
80%
Closely correlated
+6.19%
PRAX - INBX
79%
Closely correlated
-2.31%
CANF - INBX
79%
Closely correlated
-0.25%
More